FDA Approves First Factor XIa Inhibitor for Stroke Prevention

Bayer's asundexian (Sunharbo) becomes first FDA-approved drug targeting a specific protein to reduce recurrent stroke risk in high-risk patients.

The U.S. Food and Drug Administration has approved Bayer’s asundexian (brand name Sunharbo) as the first globally authorized Factor XIa inhibitor for stroke prevention. This oral medication, taken once daily, reduces the probability of recurrent stroke events in patients who have recently experienced a stroke or transient ischemic attack (‘mini’ episode) when used alongside antiplatelet therapy. The drug targets Factor XIa—a protein involved in pathological blood clotting that existing stroke medications do not address. Approximately 800,000 Americans experience stroke annually, and about 20% of survivors develop recurrent strokes within five years of their initial event. Asundexian’s approval follows positive results from a global Phase 3 clinical trial.

This advancement moves health abundance by offering a targeted intervention for a high-risk subset of stroke survivors. By reducing recurrence risk where current treatments fall short, it could lower long-term disability rates and healthcare costs for patients who have recently suffered stroke-related events. The drug’s mechanism directly addresses a previously untargeted pathway in stroke pathology, potentially improving outcomes for those at elevated risk.

What to watch: Efficacy requires concurrent antiplatelet therapy, and the approval applies only to patients with recent stroke events or transient ischemic attacks as defined by healthcare professionals. The 20% recurrence rate estimate applies specifically to survivors within five years of their initial stroke event.

Source: New Atlas